| Name | Title | Contact Details |
|---|
MGT is a national technology and advisory solutions leader serving state, local government, education (SLED) and targeted commercial clients. Our specialized solutions solve the most critical issues that live at the top of our clients leadership agenda. We partner to help clients build resilience, implement systematic change and strengthen their foundations, now and for the future. MGT is committed to impacting communities for good. For more information, visit us at mgt.us.
Bradesco Bank is a Member FDIC Equal Housing Lender. With over 50 years of experience catering to the financial needs of individual, corporate and institutional customers, our products and services have been carefully structured to serve the domestic and international markets, which, combined with our personalized service, ensures that your experience with Bradesco Bank will be unparalleled. For more information, please access: http://www.bradescobank.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We partner with low-income and working people to build economic and racial equity. We do this by confronting economic abuse and investing in community wealth. We use an ever-evolving set of legal, economic and advocacy tools to challenge and dismantle unjust systems, building quickly towards a world where all people have what they need to live and thrive.